Why Amarin Is Ready to Bounce Back

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Amarin (NASDAQ: AMRN  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Amarin and see what CAPS investors are saying about the stock right now.

Amarin facts

Headquarters (founded)

Dublin (1989)

Market Cap

$1.3 billion

Industry

Biotechnology

Trailing-12-Month EBITDA

($93.0 million)

Management

Chairman/CEO Joseph Zakrzewski
President/CFO John Thero

Trailing-12-Month Return on Equity

(115.2%)

Cash / Debt

$215.1 million / $130.8 million

Competitors

Merck (NYSE: MRK  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 94% of the 317 members who have rated Amarin believe the stock will outperform the S&P 500 going forward.

Just yesterday, one of those Fools, Kebin008, succinctly summed up the bull case for our community:

[Vascepa] is an extremely valuable asset Amarin has. I remain bullish on this stock given the CEO Joe Z's background with acquisitions. It is difficult to value the company given the uncertainty surrounding NCE status. Given the extended delay from the FDA, I believe that NCE will be granted in the end. The FDA may just simply be looking for a way to grant Amarin this designation. Furthermore, I believe that the acquisition talks will progress in a much more progressive manner once NCE status has been decided. At the current price, Amarin has great upside potential with limited downside risks.

The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (0) | Recommend This Article (4)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2159369, ~/Articles/ArticleHandler.aspx, 7/26/2014 3:31:57 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 18 hours ago Sponsored by:
DOW 16,960.57 -123.23 -0.72%
S&P 500 1,978.34 -9.64 -0.48%
NASD 4,449.56 -22.54 -0.50%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/25/2014 3:59 PM
AMRN $1.50 Down -0.07 -4.46%
Amarin Corp plc (A… CAPS Rating: ***
MRK $58.15 Down -0.06 -0.10%
Merck & Co., Inc. CAPS Rating: ***

Advertisement